Cheilbio Past Earnings Performance

Past criteria checks 0/6

Cheilbio's earnings have been declining at an average annual rate of -53.4%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been declining at an average rate of 15.7% per year.

Key information

-53.4%

Earnings growth rate

-55.2%

EPS growth rate

Pharmaceuticals Industry Growth	11.3%
Revenue growth rate	-15.7%
Return on equity	-2.6%
Net Margin	-6.7%
Last Earnings Update	30 Jun 2023

Recent past performance updates

No updates

Recent updates

A Look At The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)

Mar 15

Can You Imagine How Cheilbio's (KOSDAQ:052670) Shareholders Feel About The 83% Share Price Increase?

Jan 21

Estimating The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)

Nov 29

Revenue & Expenses Breakdown

How Cheilbio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A052670 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 23	12,713	-856	3,261	264
31 Mar 23	13,313	-1,402	3,269	250
31 Dec 22	15,349	-1,708	3,486	226
30 Sep 22	15,791	-4,133	3,694	223
30 Jun 22	15,342	-3,911	3,578	220
31 Mar 22	15,740	-1,425	3,527	211
31 Dec 21	16,912	-712	3,498	214
30 Sep 21	17,125	1,846	3,363	196
30 Jun 21	17,768	1,753	3,879	201
31 Mar 21	19,147	1,456	4,045	203
31 Dec 20	18,999	994	3,867	209
30 Sep 20	19,873	352	4,511	218
30 Jun 20	21,285	1,008	4,049	198
31 Mar 20	22,514	424	3,739	190
31 Dec 19	22,986	2,043	3,925	192
30 Sep 19	23,478	2,215	3,217	187
30 Jun 19	24,292	2,240	3,227	187
31 Mar 19	25,359	2,098	3,649	192
31 Dec 18	27,810	1,040	3,871	190
30 Sep 18	28,807	1,129	4,105	189
30 Jun 18	28,952	826	4,715	197
31 Mar 18	29,211	876	4,769	221
31 Dec 17	27,987	789	4,646	232
30 Sep 17	29,669	853	5,386	255
30 Jun 17	32,556	943	5,168	274
31 Mar 17	34,140	1,071	4,831	273
31 Dec 16	35,824	1,014	5,210	282
30 Sep 16	36,487	1,428	4,533	279
30 Jun 16	35,711	1,144	4,642	293
31 Mar 16	36,075	739	5,156	365
31 Dec 15	34,980	852	4,487	296
30 Sep 15	35,938	778	4,315	231
30 Jun 15	36,568	1,250	3,907	145
31 Mar 15	37,074	1,297	3,075	0
31 Dec 14	39,534	956	3,233	0
30 Sep 14	39,625	830	3,076	0
30 Jun 14	40,170	594	2,935	0
31 Mar 14	39,596	322	3,150	0
31 Dec 13	38,365	359	3,086	0
30 Sep 13	38,133	439	2,873	0
30 Jun 13	38,484	498	2,835	0
31 Mar 13	37,871	532	2,965	0
31 Dec 12	36,868	1,026	2,663	0

Quality Earnings: A052670 is currently unprofitable.

Growing Profit Margin: A052670 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A052670 is unprofitable, and losses have increased over the past 5 years at a rate of 53.4% per year.

Accelerating Growth: Unable to compare A052670's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A052670 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).

Return on Equity

High ROE: A052670 has a negative Return on Equity (-2.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/10/16 08:02
End of Day Share Price	2023/07/20 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cheilbio Co., Ltd. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution